Patterns of p53 immunoreactivity in endometrial carcinomas: 'all or nothing' staining is of importance

Histopathology

Volumn 59, Issue 4, 2011, Pages 786-788

  Mccluggage, W Glenn ^a   Soslow, Robert A ^b   Gilks, C Blake ^c  

^a ROYAL GROUP OF HOSPITALS TRUST   (United Kingdom)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

BARRETT ESOPHAGUS; CANCER CLASSIFICATION; CANCER GRADING; ENDOMETRIUM CARCINOMA; GENE MUTATION; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; IMMUNOREACTIVITY; LETTER; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; STAINING; UTERINE TUBE CARCINOMA;

BARRETT ESOPHAGUS; HUMANS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84860388822     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2011.03907.x     Document Type: Letter

References (16)

1. Kaye PV, Haider SA, James PD et al. Novel staining pattern of p53 in Barrett's dysplasia - the absent pattern. Histopathology 2010; 57; 933-935.
2. Hirschowitz L, Ganesan R, McCluggage WG. WT1, p53 and hormone receptor expression in uterine serous carcinoma. Histopathology 2009; 55; 478-482.
3. Alkushi A, Kobel M, Kalloger SE, Gilks CB. High-grade endometrial carcinoma: serous and grade 3 endometrioid carcinomas have different immunophenotypes and outcomes. Int. J. Gynecol. Pathol. 2010; 29; 343-350.
4. Alkushi A, Lim P, Coldman A, Huntsman D, Miller D, Gilks CB. Interpretation of p53 immunoreactivity in endometrial carcinoma: establishing a clinically relevant cut-off level. Int. J. Gynecol. Pathol. 2004; 23; 129-137.
5. Reed-Nicholson M, Iyengar P, Hummer AJ et al. Immunophenotypic diversity of endometrial adenocarcinomas: implications for differential diagnosis. Mod. Pathol. 2006; 19; 1091-1100.
6. Soong R, Knowles S, Williams KE et al. Overexpression of p53 protein is an independent prognostic indicator in human endometrial carcinoma. Br. J. Cancer 1996; 74; 562-567.
7. Ito K, Watanabe K, Nasim S et al. Prognostic significance of p53 overexpression in endometrial cancer. Cancer Res. 1994; 54; 4667-4670.
8. Powell B, Soong R, Grieu F et al. p53 protein expression is a prognostic indicator of poor survival in stage 1 endometrial carcinoma. Int. J. Oncol. 1999; 14; 175-179.
9. McCluggage WG, Connolly LE, McGregor G, Hyland P, Hall PA. A strategy for defining biologically relevant levels of p53 protein expression in clinical samples with reference to endometrial neoplasia. Int. J. Gynecol. Pathol. 2005; 24; 307-312.
10. Kobel M, Reuss A, Du Bois A et al. The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas. J. Pathol. 2010; 222; 191-198.
11. Ahmed AA, Etemadmoghadam D, Temple J et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinomas of the ovary. J. Pathol. 2010; 221; 49-56.
12. Yemelyanova A, Ji H, Shih IM et al. Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas: immunohistochemical analysis of 201 cases. Am. J. Surg. Pathol. 2009; 33; 1504-1514.
13. Chiesa-Vottero AG, Malpica A, Deavers MT et al. Immunohistochemical overexpression of p16 and p53 in uterine serous carcinoma and ovarian high-grade serous carcinoma. Int. J. Gynecol. Pathol. 2007; 26; 328-333.
14. Mhawech-Fauceglia P, Herrmann FR, Rai H et al. IMP3 distinguishes uterine serous carcinoma from endometrial endometrioid adenocarcinoma. Am. J. Clin. Pathol. 2010; 133; 899-908.
15. Zheng W, Yi X, Fadare O et al. The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma. Am. J. Surg. Pathol. 2008; 32; 304-315.
16. Garg K, Leitao MM Jr, Wynveen CA et al. p53 expression in morphologically ambiguous endometrial carcinomas correlates with adverse clinical outcomes. Mod. Pathol. 2010; 23; 80-92.